S&P 500   4,080.93 (+0.02%)
DOW   34,411.33 (-0.52%)
QQQ   293.74 (+0.13%)
AAPL   148.47 (+0.30%)
MSFT   255.79 (+0.25%)
META   120.41 (+1.96%)
GOOGL   101.25 (+0.26%)
AMZN   95.35 (-1.23%)
TSLA   194.43 (-0.14%)
NVDA   172.39 (+1.87%)
NIO   12.21 (-4.46%)
BABA   86.32 (-1.42%)
AMD   77.58 (-0.06%)
T   19.16 (-0.62%)
MU   55.53 (-3.68%)
CGC   3.88 (+7.18%)
F   14.08 (+1.29%)
GE   85.30 (-0.78%)
DIS   98.58 (+0.73%)
AMC   8.30 (+14.80%)
PYPL   78.49 (+0.10%)
PFE   51.01 (+1.76%)
NFLX   318.79 (+4.34%)
S&P 500   4,080.93 (+0.02%)
DOW   34,411.33 (-0.52%)
QQQ   293.74 (+0.13%)
AAPL   148.47 (+0.30%)
MSFT   255.79 (+0.25%)
META   120.41 (+1.96%)
GOOGL   101.25 (+0.26%)
AMZN   95.35 (-1.23%)
TSLA   194.43 (-0.14%)
NVDA   172.39 (+1.87%)
NIO   12.21 (-4.46%)
BABA   86.32 (-1.42%)
AMD   77.58 (-0.06%)
T   19.16 (-0.62%)
MU   55.53 (-3.68%)
CGC   3.88 (+7.18%)
F   14.08 (+1.29%)
GE   85.30 (-0.78%)
DIS   98.58 (+0.73%)
AMC   8.30 (+14.80%)
PYPL   78.49 (+0.10%)
PFE   51.01 (+1.76%)
NFLX   318.79 (+4.34%)
S&P 500   4,080.93 (+0.02%)
DOW   34,411.33 (-0.52%)
QQQ   293.74 (+0.13%)
AAPL   148.47 (+0.30%)
MSFT   255.79 (+0.25%)
META   120.41 (+1.96%)
GOOGL   101.25 (+0.26%)
AMZN   95.35 (-1.23%)
TSLA   194.43 (-0.14%)
NVDA   172.39 (+1.87%)
NIO   12.21 (-4.46%)
BABA   86.32 (-1.42%)
AMD   77.58 (-0.06%)
T   19.16 (-0.62%)
MU   55.53 (-3.68%)
CGC   3.88 (+7.18%)
F   14.08 (+1.29%)
GE   85.30 (-0.78%)
DIS   98.58 (+0.73%)
AMC   8.30 (+14.80%)
PYPL   78.49 (+0.10%)
PFE   51.01 (+1.76%)
NFLX   318.79 (+4.34%)
S&P 500   4,080.93 (+0.02%)
DOW   34,411.33 (-0.52%)
QQQ   293.74 (+0.13%)
AAPL   148.47 (+0.30%)
MSFT   255.79 (+0.25%)
META   120.41 (+1.96%)
GOOGL   101.25 (+0.26%)
AMZN   95.35 (-1.23%)
TSLA   194.43 (-0.14%)
NVDA   172.39 (+1.87%)
NIO   12.21 (-4.46%)
BABA   86.32 (-1.42%)
AMD   77.58 (-0.06%)
T   19.16 (-0.62%)
MU   55.53 (-3.68%)
CGC   3.88 (+7.18%)
F   14.08 (+1.29%)
GE   85.30 (-0.78%)
DIS   98.58 (+0.73%)
AMC   8.30 (+14.80%)
PYPL   78.49 (+0.10%)
PFE   51.01 (+1.76%)
NFLX   318.79 (+4.34%)
LON:DPH

Dechra Pharmaceuticals - DPH Share Forecast, Price & News

GBX 2,808.54
+88.54 (+3.26%)
(As of 12/1/2022 05:03 PM ET)
Add
Compare
Today's Range
2,770
2,832
50-Day Range
2,524
2,968
52-Week Range
2,487.45
5,395
Volume
238,380 shs
Average Volume
331,784 shs
Market Capitalization
£3.20 billion
P/E Ratio
5,299.13
Dividend Yield
1.68%
Price Target
GBX 4,142.50

Dechra Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
47.5% Upside
GBX 4,142.50 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
£5.38 M Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.67 out of 5 stars

DPH stock logo

About Dechra Pharmaceuticals (LON:DPH) Stock

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. The company operates in the United Kingdom, Germany, rest of Europe, the United States, and internationally. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.

Receive DPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dechra Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DPH Stock News Headlines

Dechra Pharmaceuticals
2 FTSE 100 shares I’d buy as stocks fall
2 FTSE 100 growth stocks to buy right now
Dechra Pharma HY Revenue Up 15% At CER - Quick Facts
Dechra Pharmaceuticals (LSE:DPH)
See More Headlines
Receive DPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dechra Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DPH Company Calendar

Ex-Dividend for 11/18 Dividend
10/27/2022
Dividend Payable
11/18/2022
Today
12/01/2022

Industry, Sector and Symbol

Industry
Drug Manufacturers - Major
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
1,699
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
GBX 4,142.50
High Stock Price Forecast
GBX 5,700
Low Stock Price Forecast
GBX 2,850
Forecasted Upside/Downside
+47.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£681.80 million
Cash Flow
GBX 114.04 per share
Book Value
GBX 615.20 per share

Miscellaneous

Free Float
N/A
Market Cap
£3.20 billion
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Ian D. Page (Age 61)
    CEO, MD & Exec. Director
    Comp: $1.26M
  • Mr. Paul Nicholas Sandland MAAT (Age 43)
    FCCA, CFO & Exec. Director
    Comp: $790k
  • Dr. Anthony Gerard Griffin (Age 59)
    MD of Dechra Veterinary Products for Europe & Exec. Director
    Comp: $601k
  • Mr. Patrick Meeus
    Group Scientific Officer
  • Ms. Katy Clough
    Group HR Director
  • Mr. Mike Eldred (Age 52)
    Pres of North America
  • Ms. Melanie Hall
    Company Sec.













DPH Stock - Frequently Asked Questions

Should I buy or sell Dechra Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dechra Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DPH shares.
View DPH analyst ratings
or view top-rated stocks.

What is Dechra Pharmaceuticals' stock price forecast for 2023?

4 equities research analysts have issued 1 year price objectives for Dechra Pharmaceuticals' stock. Their DPH share price forecasts range from GBX 2,850 to GBX 5,700. On average, they expect the company's share price to reach GBX 4,142.50 in the next year. This suggests a possible upside of 47.5% from the stock's current price.
View analysts price targets for DPH
or view top-rated stocks among Wall Street analysts.

How have DPH shares performed in 2022?

Dechra Pharmaceuticals' stock was trading at GBX 5,325 at the beginning of the year. Since then, DPH stock has decreased by 47.3% and is now trading at GBX 2,808.54.
View the best growth stocks for 2022 here
.

How often does Dechra Pharmaceuticals pay dividends? What is the dividend yield for Dechra Pharmaceuticals?

Dechra Pharmaceuticals declared a dividend on Monday, September 5th. Stockholders of record on Thursday, October 27th will be paid a dividend of GBX 32.89 per share on Friday, November 18th. This represents a yield of 0.99%. The ex-dividend date of this dividend is Thursday, October 27th. This is a boost from the stock's previous dividend of GBX 12. The official announcement can be viewed at this link.
Read our dividend analysis for DPH
.

Is Dechra Pharmaceuticals a good dividend stock?

Dechra Pharmaceuticals (LON:DPH) pays an annual dividend of GBX 0.41 per share and currently has a dividend yield of 1.68%. The dividend payout ratio is 78.09%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for DPH.

What other stocks do shareholders of Dechra Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dechra Pharmaceuticals investors own include 32Red (TTR), 1428686 (SGP.L) (SGP), JD Sports Fashion (JD), Ashtead Group (AHT), Cranswick (CWK), Drax Group (DRX), RPC Group (RPC), Robert Walters (RWA), SEB (SKP) and Barratt Developments (BDEV).

What is Dechra Pharmaceuticals' stock symbol?

Dechra Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "DPH."

How do I buy shares of Dechra Pharmaceuticals?

Shares of DPH stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Dechra Pharmaceuticals' stock price today?

One share of DPH stock can currently be purchased for approximately GBX 2,808.54.

How much money does Dechra Pharmaceuticals make?

Dechra Pharmaceuticals (LON:DPH) has a market capitalization of £3.20 billion and generates £681.80 million in revenue each year.

How many employees does Dechra Pharmaceuticals have?

The company employs 1,699 workers across the globe.

How can I contact Dechra Pharmaceuticals?

Dechra Pharmaceuticals' mailing address is 24 Cheshire Business Park Cheshire Avenue, NORTHWICH, CW9 7UA, United Kingdom. The official website for the company is www.dechra.com. The company can be reached via phone at +44-1606-814730.

This page (LON:DPH) was last updated on 12/1/2022 by MarketBeat.com Staff